News Archives - NetworkNewsWire

FridayJan 10, 2020 7:30 am

NetworkNewsAudio – Veteran Graphite Mining and Upgrading Executive Don Baxter Joins the Board of Ceylon Graphite Corp. (TSX.V: CYL) (OTC: CYLYF) (FSE: CCY)

Related Press Release Ceylon Graphite Corp. (TSX.V: CYL) (OTC: CYLYF) (FSE: CCY) announced that Don Baxter has joined the Board of Directors of the company. Don Baxter is one of the premier graphite experts outside of China, having built one of only two producing graphite mines in North America. He is presently Chief Executive Officer and Director of Applied Graphite Technologies Corp. Prior to this, Don served as President, CEO and Executive Director of Alabama Graphite Corp, successfully completing the company’s disruptive Preliminary Economic Assessment (PEA) and introducing a new, battery-focused strategy. View Original Press Release About NetworkNewsAudio NetworkNewsAudio, a…

MondayDec 23, 2019 8:00 am

NetworkNewsAudio – InvestorBrandNetwork Concludes Coverage and 5th Year of Sponsorship of LD Micro Main Event

Related Press Release InvestorBrandNetwork (“IBN”), an innovative corporate communications agency, content distributor and wire-grade press service via NetworkNewsWire, has completed its coverage of the 12th annual LD Micro Main Event, one of the largest and most influential independent conferences in the small-cap space. A five-year sponsor of LD Micro, IBN attended this year’s Main Event to engage with executives from the 275+ public companies that presented at the conference. IBN also provided widespread exposure through published corporate overviews and delivered real-time social media coverage for participating companies. View Original Press Release About InvestorBrandNetwork (IBN) The InvestorBrandNetwork (IBN) consists of financial brands introduced to the investment…

ThursdayDec 05, 2019 8:00 am

NetworkNewsAudio – Sigma Labs Inc. (NASDAQ: SGLB) Pioneering PrintRite3D(R) Software Enables Real Time Error Correction

Related Editorial 3D-printing technology has arrived and appears ready to beneficially disrupt every field it touches. Additive manufacturing, better known as three-dimensional or 3D printing, has potential to change the world. However, the full promise of the technology has been stymied due to the high costs and complexities of end-product inspection and quality control. With its pioneering PrintRite3D(R) software, Sigma Labs Inc. (NASDAQ: SGLB) (SGLB Profile) appears to be ready to help unleash the transformative forces of 3D printing and usher in what’s been called the fourth industrial revolution. Aerospace has embraced 3D printing and, for the first time in…

ThursdayNov 21, 2019 8:00 am

NetworkNewsAudio – Sigma Labs Inc. (NASDAQ: SGLB) Transforming Commercial Additive Manufacturing with PrintRite3D Software

Related Editorial Heralded as the fourth industrial revolution, 3D printing is about to transform the $12 trillion global manufacturing sector. Sigma Labs Inc. (NASDAQ: SGLB) (SGLB Profile) is on the verge of unleashing the dynamic forces of additive metal manufacturing that have been restrained. Long heralded as the fourth industrial revolution, 3D metal printing and its full potential have been stalled due to the high cost and complexities of end-product inspection and quality control. Sigma Labs’ PrintRite3D(R) software represents a seismic shift in the quality-assurance process in the manufacture of 3D-printed metal components, and the entire sector is poised for…

ThursdayNov 07, 2019 8:00 am

NetworkNewsAudio – Wonderfilm Media Corp. (TSX.V: WNDR) (OTCQB: WDRFF) Seeks to Capitalize on Surging Video-Streaming Market

Related Editorial As video streaming grows to dominate media consumption, companies are on the lookout for new ways to profit from the burgeoning trend. Wonderfilm Media Corporation (TSXV: WNDR) (OTCQB: WDRFF) (WDRFF Profile) has developed a low-risk approach to content production by providing original works with top Hollywood talent. Apple Inc. (NASDAQ: AAPL) is launching its new TV+ service with a slew of big-name stars and big-budget productions. Netflix Inc. (NASDAQ: NFLX) continues to be a dominant player, with a strong mix of original and established content. The Walt Disney Company (NYSE: DIS) is using its range of high-profile entertainment…

ThursdayNov 07, 2019 8:00 am

NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) Subsidiary Leverages Extensive Molecular Information Platform to Accelerate New Drug Development

Related Editorial Despite the enormous progress made in the war against cancers, ovarian cancer has proved to be a tenacious foe. Progress is being made, however, as AI predictive models are being used to better target deadly ovarian cancers. Ovarian cancer is difficult to treat and lethal, with survival rates much lower than other cancers that affect women. Recently, the battle against ovarian cancer has shifted strategy, and new optimism has come to the fore. Predictive models using artificial intelligence on large data sets of patient drug-treatment protocols and historical outcomes are now providing actionable intelligence for pharma to develop…

ThursdayOct 31, 2019 8:00 am

NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) Leveraging Vast Database of Drug-Response, Outcome Data

Related Editorial The field of precision medicine has latched upon what may well be the Holy Grail in the fight against cancer. When big data are utilized by teams of pathologists, data can be incredibly helpful, but when the right data are comprehensively analyzed by artificial intelligence (AI)-powered models, the data can be downright lifesaving. Predictive Oncology (NASDAQ: POAI) (POAI Profile) is in an enviable position in the precision-medicine industry due to its incredibly rich data set of more than 150,000 clinically validated cases on its molecular information platform, with 30,000-plus specific to ovarian cancer. The company is leveraging this…

ThursdaySep 26, 2019 8:00 am

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Building Encouraging New Breast Cancer Treatment Options

Related Editorial Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.’s (NASDAQ: GNPX) (GNPX Profile) TUSC2 prevented tumor growth against triple-negative breast cancer. Eli Lilly and Company (NYSE: LLY) is focusing on those patients with the greatest need and, in the process, has developed a new breast-cancer treatment option. Roche Holding (OTCQX: RHHBY) is expanding the use of its biotech to both identify and treat patients with challenging breast cancers. AbbVie Inc. (NYSE: ABBV) has been rapidly increasing its research, targeting more than 15 different types of cancer. AstraZeneca…

FridaySep 06, 2019 8:00 am

NetworkNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Making Significant Advances in Drug Delivery

Related Editorial Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has developed one of the most innovative drug-delivery systems seen in years, a system that can be used to deliver a wide range of drugs in a more palatable and effective…

FridayAug 23, 2019 8:00 am

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Making Headway in Clinical Program Expansion, Company Growth

Related Editorial Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) has completed key steps in its overall strategy to expand its clinical development programs and bring Oncoprex(TM) immunogene therapy, its lead drug candidate, to commercialization. Over the past five years, Amgen Inc. (NASDAQ: AMGN) has invested nearly $19 billion in R&D and, as a result, is now advancing a record number of clinical assets. Biogen Inc. (NASDAQ: BIIB) has added four new programs to…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Audio Categories: News